Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.47 |
| ▸ | CES1 | P23141 | 2/20 | 0.47 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.47 |
| ▸ | VNN1 | O95497 | 4/20 | 0.43 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.43 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | KDM5A | P29375 | 1/20 | 0.36 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.36 |
| ▸ | HSD17B14 | Q9BPX1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13664918 | 0.88 | CES2 (0.44) | CES2CES1SRD5A2VNN1CYP4F2 | |
| SCHEMBL1002846 | 0.83 | CES2 (0.53) | CES2CES1VNN1CYP4F2CYP4A11 | |
| SCHEMBL1426328 | 0.79 | CES2 (0.48) | CES2CES1VNN1CYP4F2CYP4A11 | |
| SCHEMBL93021 | 0.78 | CYP4F2 (0.50) | CES2CES1CYP4F2CYP4A11MAOA | |
| SCHEMBL1004288 | 0.78 | SRD5A2 (0.43) | CES2CES1SRD5A2CYP4F2CYP4A11 | |
| SCHEMBL542783 | 0.77 | PRKAB2 (0.49) | CES2CES1SRD5A2CYP4F2CYP4A11 | |
| SCHEMBL7967901 | 0.74 | CES2 (0.73) | CES2CES1VNN1HSD17B14 | |
| SCHEMBL31413134 | 0.74 | DGAT1 (0.56) | CES2CES1CYP4F2CYP4A11MAOB | |
| SCHEMBL4048125 | 0.74 | MAOB (0.54) | CES2CES1CYP4F2CYP4A11MAOA | |
| SCHEMBL1534957 | 0.74 | VNN1 (0.49) | CES2CES1VNN1MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247560-A1 | Diaryl ketimine derivative | BANYU PHARMACEUTICAL CO., LTD. | 2009-10-01 | — | — | US | disclosed |
| US-20090247560-A1 | Diaryl ketimine derivative | BANYU PHARMACEUTICAL CO., LTD. | 2009-10-01 | — | — | US | disclosed |
| EP-2072519-A1 | DIARYL KETIMINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247560-A1 | Diaryl ketimine derivative | NR0B2, NR2C2, NR3C2 | CES2 1262/4885CES1 758/4885SRD5A2 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.